Malaysia Gaming Sector's Recovery May Remain Intact -- Market Talk

Dow Jones

01-27

0208 GMT - The recovery trajectory for Malaysian casino operators is expected to remain robust, driven by rebounding travel demand and visa-free travel pacts between China, Malaysia and Singapore, Hong Leong IB analyst Chee Kok Siang says in a note. He highlights key developments to watch, including Resorts World New York City's bid for a New York casino license, with results expected in late 2025, and Genting Malaysia's potential entry into Thailand's Entertainment Complex. Hong Leong maintains an overweight rating on the gaming sector and pegs Genting as its preferred pick given its strong position to benefit from the recovery of its units Genting Singapore and Genting Malaysia, and potential gains if its associate TauRx Pharmaceuticals' hydromethylthionine mesylate drug secures an FDA approval. (yingxian.wong@wsj.com)

(END) Dow Jones Newswires

January 26, 2025 21:08 ET (02:08 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2506315733"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2506315733\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2506315733?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-27 10:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2506315733","market":"fut","top_or_hot":-1,"title":"Malaysia Gaming Sector's Recovery May Remain Intact -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0208 GMT - The recovery trajectory for Malaysian casino operators is expected to remain robust, driven by rebounding travel demand and visa-free travel pacts between China, Malaysia and Singapore, Hong Leong IB analyst Chee Kok Siang says in a note. He highlights key developments to watch, including Resorts World New York City's bid for a New York casino license, with results expected in late 2025, and Genting Malaysia's potential entry into Thailand's Entertainment Complex. Hong Leong maintains an overweight rating on the gaming sector and pegs Genting as its preferred pick given its strong position to benefit from the recovery of its units Genting Singapore and Genting Malaysia, and potential gains if its associate TauRx Pharmaceuticals' hydromethylthionine mesylate drug secures an FDA approval. (yingxian.wong@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 26, 2025 21:08 ET (02:08 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Malaysia Gaming Sector's Recovery May Remain Intact -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMalaysia Gaming Sector's Recovery May Remain Intact -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-27 10:08</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0208 GMT - The recovery trajectory for Malaysian casino operators is expected to remain robust, driven by rebounding travel demand and visa-free travel pacts between China, Malaysia and Singapore, Hong Leong IB analyst Chee Kok Siang says in a note. He highlights key developments to watch, including Resorts World New York City's bid for a New York casino license, with results expected in late 2025, and Genting Malaysia's potential entry into Thailand's Entertainment Complex. Hong Leong maintains an overweight rating on the gaming sector and pegs Genting as its preferred pick given its strong position to benefit from the recovery of its units Genting Singapore and Genting Malaysia, and potential gains if its associate TauRx Pharmaceuticals' hydromethylthionine mesylate drug secures an FDA approval. (yingxian.wong@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 26, 2025 21:08 ET (02:08 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999016042.SGD","symbol_name":"Schroder Singapore Trust A Acc SGD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2506315733","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2506315733","pubTimestamp":1737943680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Copyright (c) 2025 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999016042.SGD":"Schroder Singapore Trust A Acc SGD","SG9999014484.SGD":"Nikko AM ASEAN Equity Fund A SGD","SG9999005177.SGD":"Legg Mason Martin Currie - Southeast Asia Trust A Acc SGD","SG9999000343.SGD":"Schroder Singapore Trust A Dis SGD","SGXZ27511609.SGD":"NIKKO AM SINGAPORE DIVIDEND EQUITY \"SGD\" (SGD) ACC","G13.SI":"云顶新加坡","BK6066":"赌场与赌博","SG9999014492.USD":"NIKKO AM ASEAN EQUITY \"A\" (USD) ACC","SG9999003826.SGD":"日兴资管新加坡股息基金 SGD","BK6505":"周期性消费品与消费者服务","SG9999004360.SGD":"Nikko AM Shenton Thrift Fund SGD"},"translate_title":"马来西亚博彩业的复苏可能保持不变——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"G13.SI":0.9},"content_text":"0208 GMT - The recovery trajectory for Malaysian casino operators is expected to remain robust, driven by rebounding travel demand and visa-free travel pacts between China, Malaysia and Singapore, Hong Leong IB analyst Chee Kok Siang says in a note. He highlights key developments to watch, including Resorts World New York City's bid for a New York casino license, with results expected in late 2025, and Genting Malaysia's potential entry into Thailand's Entertainment Complex. Hong Leong maintains an overweight rating on the gaming sector and pegs Genting as its preferred pick given its strong position to benefit from the recovery of its units Genting Singapore and Genting Malaysia, and potential gains if its associate TauRx Pharmaceuticals' hydromethylthionine mesylate drug secures an FDA approval. (yingxian.wong@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 26, 2025 21:08 ET (02:08 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}